{"transactions":[{"id":2340069,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":129265,"kind":"person","name":"Besthof Robert","position":1,"cik":"0001864650","reported_name":"Besthof Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim CEO"}}],"security":"Employee Stock Option","published_at":"2022-03-10T16:04:19.000Z","date":"2022-03-08","kind":"grant","acquired":true,"shares":100000,"price":2.61,"value":261000.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options issued under the NRX Pharmaceuticals, Inc. 2021 Omnibus Incentive Plan. The options vest on March 8, 2023, generally subject to the Reporting Person's continued service for NRX Pharmaceuticals, Inc."}],"balance_after":347200,"derivative":{"exercise_price":2.61,"expiration_date":"2032-03-08","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0000950142-22-000997","document":"es220233694_4-besthof.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1864650/000095014222000997/es220233694_4-besthof.xml","form_type":"4"}},{"id":2529259,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":129265,"kind":"person","name":"Besthof Robert","position":1,"cik":"0001864650","reported_name":"Besthof Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Comm. & Patient Officer"}}],"security":"Restricted Stock Units","published_at":"2021-11-02T16:04:47.000Z","date":"2021-08-16","kind":"grant","acquired":true,"shares":36290,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Shares and restricted stock units acquired pursuant to the exercise of 100,000 vested stock options under the NRX Pharmaceuticals, Inc. 2021 Omnibus Incentive Plan (the \"Plan\"). The Reporting person received 63,701 freely tradable shares of common stock, par value $0.001 per share, of NRX Pharmaceuticals, Inc. (the \"Common Stock\") and 36,290 restricted stock units, each restricted stock unit representing a right to receive one share of Common Stock. The restricted stock units remain in the Plan and are subject to forfeiture if the Earnout Share Milestone and the Earnout Cash Milestone (as defined in the Merger Agreement) do not occur on or prior to December 31, 2022."},{"field":"shares","element":"transactionShares","label":"F2","text":"Shares and restricted stock units acquired pursuant to the exercise of 100,000 vested stock options under the NRX Pharmaceuticals, Inc. 2021 Omnibus Incentive Plan (the \"Plan\"). The Reporting person received 63,701 freely tradable shares of common stock, par value $0.001 per share, of NRX Pharmaceuticals, Inc. (the \"Common Stock\") and 36,290 restricted stock units, each restricted stock unit representing a right to receive one share of Common Stock. The restricted stock units remain in the Plan and are subject to forfeiture if the Earnout Share Milestone and the Earnout Cash Milestone (as defined in the Merger Agreement) do not occur on or prior to December 31, 2022."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Shares and restricted stock units acquired pursuant to the exercise of 100,000 vested stock options under the NRX Pharmaceuticals, Inc. 2021 Omnibus Incentive Plan (the \"Plan\"). The Reporting person received 63,701 freely tradable shares of common stock, par value $0.001 per share, of NRX Pharmaceuticals, Inc. (the \"Common Stock\") and 36,290 restricted stock units, each restricted stock unit representing a right to receive one share of Common Stock. The restricted stock units remain in the Plan and are subject to forfeiture if the Earnout Share Milestone and the Earnout Cash Milestone (as defined in the Merger Agreement) do not occur on or prior to December 31, 2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Shares and restricted stock units acquired pursuant to the exercise of 100,000 vested stock options under the NRX Pharmaceuticals, Inc. 2021 Omnibus Incentive Plan (the \"Plan\"). The Reporting person received 63,701 freely tradable shares of common stock, par value $0.001 per share, of NRX Pharmaceuticals, Inc. (the \"Common Stock\") and 36,290 restricted stock units, each restricted stock unit representing a right to receive one share of Common Stock. The restricted stock units remain in the Plan and are subject to forfeiture if the Earnout Share Milestone and the Earnout Cash Milestone (as defined in the Merger Agreement) do not occur on or prior to December 31, 2022."}],"balance_after":36290,"derivative":{"underlying":"Common Stock","underlying_shares":36290},"source":{"system":"sec-edgar","filing":"0000950142-21-003503","document":"es210197021_4-besthof.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1864650/000095014221003503/es210197021_4-besthof.xml","form_type":"4"}},{"id":2529258,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":129265,"kind":"person","name":"Besthof Robert","position":1,"cik":"0001864650","reported_name":"Besthof Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Comm. & Patient Officer"}}],"security":"Employee Stock Option (Right to buy)","published_at":"2021-11-02T16:04:47.000Z","date":"2021-08-16","kind":"exercise","acquired":false,"shares":100000,"price":0.2,"value":20000.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options are fully vested."}],"balance_after":247200,"derivative":{"exercise_price":0.2,"expiration_date":"2026-03-01","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0000950142-21-003503","document":"es210197021_4-besthof.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1864650/000095014221003503/es210197021_4-besthof.xml","form_type":"4"}},{"id":2529257,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":129265,"kind":"person","name":"Besthof Robert","position":1,"cik":"0001864650","reported_name":"Besthof Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Comm. & Patient Officer"}}],"security":"Common Stock","published_at":"2021-11-02T16:04:47.000Z","date":"2021-09-15","kind":"sale","acquired":false,"shares":40000,"price":11.76,"value":470400.0,"ownership":{"direct":true},"balance_after":23710,"source":{"system":"sec-edgar","filing":"0000950142-21-003503","document":"es210197021_4-besthof.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1864650/000095014221003503/es210197021_4-besthof.xml","form_type":"4"}},{"id":2529256,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":129265,"kind":"person","name":"Besthof Robert","position":1,"cik":"0001864650","reported_name":"Besthof Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Comm. & Patient Officer"}}],"security":"Common Stock","published_at":"2021-11-02T16:04:47.000Z","date":"2021-08-16","kind":"exercise","acquired":true,"shares":63710,"price":0.2,"value":12742.0,"ownership":{"direct":true},"footnotes":[{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"The options are fully vested."}],"balance_after":63710,"source":{"system":"sec-edgar","filing":"0000950142-21-003503","document":"es210197021_4-besthof.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1864650/000095014221003503/es210197021_4-besthof.xml","form_type":"4"}},{"id":2674213,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":129265,"kind":"person","name":"Besthof Robert","position":1,"cik":"0001864650","reported_name":"Besthof Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Comm. & Patient Officer"}}],"security":"Employee Stock Option (Right to buy)","published_at":"2021-06-10T18:44:45.000Z","date":"2021-05-24","kind":"grant","acquired":true,"shares":347200,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Subject to certain conditions, the options will generally vest in five equal installments of 20% on each of 10/23/21, 10/23/22, 10/23/23, 10/23/24 and 10/23/25."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Merger Agreement, each option and warrant of NeuroRx that was outstanding and unexercised immediately prior to the Effective Time was assumed by NRX Pharmaceuticals (each, a \"Substitute Security\") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement. In the event that any Substitute Security is exercised prior to the earlier of the date on which both the Earnout Share Milestone and the Earnout Cash Milestone (as defined in the Merger Agreement) have been achieved and December 31, 2022, a number of shares of the Issuer's common stock will be subject to forfeiture pursuant to the Option Post-Earnout Adjustment (as defined in the Merger Agreement)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Subject to certain conditions, the options will generally vest in five equal installments of 20% on each of 10/23/21, 10/23/22, 10/23/23, 10/23/24 and 10/23/25."}],"balance_after":347200,"derivative":{"exercise_price":3.08,"expiration_date":"2030-10-23","underlying":"Common Stock","underlying_shares":347200},"source":{"system":"sec-edgar","filing":"0000950142-21-001936","document":"es210157180_4-besthof.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1864650/000095014221001936/es210157180_4-besthof.xml","form_type":"4"}},{"id":2674212,"issuer":{"id":6523,"kind":"organization","name":"NRX Pharmaceuticals, Inc."},"owners":[{"id":129265,"kind":"person","name":"Besthof Robert","position":1,"cik":"0001864650","reported_name":"Besthof Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Comm. & Patient Officer"}}],"security":"Employee Stock Option (Right to buy)","published_at":"2021-06-10T18:44:45.000Z","date":"2021-05-24","kind":"grant","acquired":true,"shares":347200,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Subject to certain conditions, the options will generally vest in five equal installments of 20% on each of 10/23/21, 10/23/22, 10/23/23, 10/23/24 and 10/23/25."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Merger Agreement, each option and warrant of NeuroRx that was outstanding and unexercised immediately prior to the Effective Time was assumed by NRX Pharmaceuticals (each, a \"Substitute Security\") and represents the right to acquire an adjusted number of shares of Common Stock at an adjusted exercise price, in each case, pursuant to the terms of the Merger Agreement. In the event that any Substitute Security is exercised prior to the earlier of the date on which both the Earnout Share Milestone and the Earnout Cash Milestone (as defined in the Merger Agreement) have been achieved and December 31, 2022, a number of shares of the Issuer's common stock will be subject to forfeiture pursuant to the Option Post-Earnout Adjustment (as defined in the Merger Agreement)."}],"balance_after":347200,"derivative":{"exercise_price":0.21,"expiration_date":"2026-03-01","underlying":"Common Stock","underlying_shares":347200},"source":{"system":"sec-edgar","filing":"0000950142-21-001936","document":"es210157180_4-besthof.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1864650/000095014221001936/es210157180_4-besthof.xml","form_type":"4"}}]}